“`html
Gentler Cell Retrieval Method Boosts Promise of Cancer Immunotherapy
A new technique developed by researchers at the Indian Institute of Technology Bombay (IIT Bombay) promises to significantly improve the efficiency of T-cell based immunotherapies, offering renewed hope in the fight against cancer. The breakthrough addresses a critical challenge in these advanced treatments: gently and effectively retrieving modified T-cells after they’ve been grown in the laboratory.
Understanding the Power of Immunotherapy
Immunotherapy, which harnesses the bodyS own immune system to recognize and destroy cancer cells, has emerged as a powerful tool in modern oncology. Treatments like CAR T-cell therapy involve extracting a patient’s T-cells – a type of immune cell – modifying them to better target cancer, and then infusing them back into the bloodstream. A key hurdle,tho,lies in ensuring a sufficient supply of healthy,active T-cells for these therapies.
“Finding safe and efficient ways to grow T-cells and retrieve them is therefore an important part of making these therapies work,” explains a leading researcher involved in the study.
The Challenge of 3D Cell Growth
Traditionally, T-cells are grown in two dimensions (2D), but this doesn’t accurately reflect the complex 3D environment within the body. To overcome this, researchers are increasingly turning to 3D cell culture techniques, using scaffolds to provide a more natural setting for cell growth. However, this introduces a new problem: getting the cells *off* the scaffold without damaging them.
“When you grow cells in 3D, they tend to adhere strongly to the scaffold, making retrieval arduous. This is especially true for T-cells, which are surprisingly tenacious when they grip onto a surface,” says Prof. Samir Tayalia, who led the research at IIT Bombay.
This difficulty in retrieval can significantly reduce the number of viable cells available for therapy.”
A New Approach to Cell Recovery
To tackle this issue, the research team, in collaboration wiht Prof. Neil Cameron of Monash University, focused on optimizing the cell retrieval process. They grew Jurkat T-cells – a common cell line used in immunological research – within electrospun scaffolds made from polycaprolactone. Microscopic observation revealed that the cells actively migrated into the scaffold and became firmly lodged between the fibers. Simple flushing proved ineffective at dislodging the cells, particularly those at fiber junctions.
“Theoretically, T-cells are considered easy to handle as they are ‘suspension cells’-they usually float freely in liquid. In reality, when placed inside a dense fibre network, they grip tightly,” noted dr. Jaydeep Das, the study’s first author.
The team then compared three different cell recovery methods: manual flushing, TrypLE (an enzyme used to detach cells), and Accutase, a gentler enzymatic choice. They assessed the number of cells recovered, cell viability, and their ability to continue growing. While all three methods yielded comparable cell recovery rates, Accutase consistently resulted in a higher percentage of viable cells.
Accutase preserves T-Cell Function
further analysis revealed that cells recovered using TrypLE exhibited higher rates of cell death and a loss of crucial immune functions. in contrast,cells recovered with Accutase maintained their viability and continued to behave like healthy T-cells,forming clusters – a necesary step before cell division – and demonstrating robust growth.
“Harsh treatments to cells, using enzymes such as trypsin, can damage key surface proteins needed for immune signalling and activation, reducing the cell’s therapeutic usefulness. Accutase appears mild enough to avoid this problem,” Prof. Tayalia explained.
The findings,published in the journal Biomaterials Science,suggest that Accutase could become a standard practice in laboratories preparing cells for advanced therapies like CAR T-cell treatment.
“If we want these advanced therapies to reach patients,every step matters. How we grow cells, and how we retrieve them, can make a real difference,” Prof. Tayalia emphasized.
Future Directions
Building on this success, the team has already demonstrated that T-cells grown on scaffolds and recovered using Accutase are more effective at killing cancer cells. Their future research will focus on testing these findings in animal models and exploring the possibility of directly implanting T-cell-loaded scaffolds into the body.
